Stocktoria
Arcadia Biosciences, Inc. RKDA
Arcadia Biosciences, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.9M | $5.0M | $4.5M | $7.4M | $6.8M | $8.0M | $1.2M | $1.5M | $4.0M | $3.2M |
| R&D expense | $9,000 | $53,000 | $64,000 | $1.5M | $3.9M | $8.0M | $7.1M | $6.1M | $7.4M | $8.7M |
| SG&A expense | $7.0M | $9.6M | $8.2M | $15.0M | $22.9M | $16.5M | $13.6M | $11.6M | $10.7M | $12.2M |
| Operating income | -$2.5M | -$3.6M | -$6.1M | -$14.0M | -$35.5M | -$12.8M | -$19.4M | -$16.9M | -$14.3M | -$18.6M |
| Interest expense | — | — | — | — | $20,000 | $47,000 | $5,000 | — | $747,000 | $1.3M |
| Income tax | $8,000 | $8,000 | $8,000 | $14,000 | $2,000 | -$124,000 | $2,000 | $10,000 | $26,000 | $25,000 |
| Net income | -$2.3M | -$7.0M | -$14.0M | -$15.4M | -$14.7M | -$4.7M | -$28.8M | -$13.5M | -$15.7M | -$19.6M |
| EPS (diluted) | $-1.71 | $-5.17 | $-11.29 | $-25.65 | $-27.56 | — | — | — | — | — |
| Operating cash flow | -$4.7M | -$9.6M | -$15.3M | -$14.0M | -$25.9M | -$30.2M | -$17.2M | -$13.6M | -$14.0M | -$17.1M |
| Free cash flow | -$4.7M | -$9.6M | -$15.3M | -$14.0M | -$26.9M | -$32.6M | -$18.7M | -$13.9M | -$14.0M | -$17.3M |
| Cash & equivalents | $259,000 | $4.2M | $6.5M | $20.6M | $28.7M | $14.0M | $8.4M | $12.0M | $9.1M | $2.0M |
| Inventory | $1.2M | $904,000 | $837,000 | $2.3M | $4.4M | $3.8M | $1.8M | $181,000 | $229,000 | $252,000 |
| Total assets | $6.5M | $13.5M | $19.7M | $28.9M | $43.9M | $47.3M | $32.6M | $24.0M | $16.6M | $56.6M |
| Total liabilities | $2.4M | $7.3M | $7.0M | $8.0M | $12.7M | $18.8M | $24.2M | $11.2M | $8.6M | $34.4M |
| Shareholders' equity | $4.1M | $6.2M | $12.8M | $21.0M | $31.2M | $28.6M | $8.3M | $12.8M | $8.0M | $22.2M |
Growth · year-over-year · Revenue CAGR 4.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -3.7% | +13.3% | -40.0% | +9.4% | -15.6% | +587.3% | -20.2% | -63.6% | +26.3% | -41.1% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.